Union européenne - français - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - autres agents antinéoplasiques - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Union européenne - français - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - le myélome multiple - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Union européenne - français - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - agents antinéoplasiques - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

roche - tocilizumab - solution à diluer pour perfusion

Union européenne - français - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymphome, cellule du manteau - agents antinéoplasiques - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Canada - français - Health Canada

gilead sciences canada inc - brexucabtagène autoleucel - suspension - 200000000cellules - brexucabtagène autoleucel 200000000cellules - antineoplastic agents

Canada - français - Health Canada

gilead sciences canada inc - brexucabtagène autoleucel - suspension - 100000000cellules - brexucabtagène autoleucel 100000000cellules

Canada - français - Health Canada

hoffmann-la roche limited - glofitamab - solution - 10mg - glofitamab 10mg

Canada - français - Health Canada

hoffmann-la roche limited - glofitamab - solution - 2.5mg - glofitamab 2.5mg

Canada - français - Health Canada

celgene inc - lisocabtagène maraleucel - suspension - 120000000cellules - lisocabtagène maraleucel 120000000cellules